Rituximab during pregnancy in neuromyelitis optica: A case report

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 1;6(2):e542. doi: 10.1212/NXI.0000000000000542. eCollection 2019 Mar.

Authors

Jahir Miranda-Acuña¹, Erica Rivas-Rodríguez¹, Michael Levy¹, Mustafa Ansari¹, Roslynn Stone¹, Vivek Patel¹, Lilyana Amezcua¹

Affiliation

¹ USC MS Comprehensive Care Center (J.M.-A., E.R.-R., M.A., L.A.), Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA; Department of Neurology (M.L.), Johns Hopkins University, Baltimore, MD; Department of Neurology and Pharmacology (R.S.), University of Southern California; and Department of Ophthalmology (V.P.), Roski Eye Institute, University of Southern California, Los Angeles, CA.

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Aquaporin 4 / immunology
Female
Humans
Infant, Newborn
Neuromyelitis Optica / drug therapy*
Postpartum Period
Pregnancy
Rituximab / therapeutic use*
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Aquaporin 4
Rituximab